Dexcom G8 announced, and it’s half the size of G7

Dexcom has given the type 1 diabetes community its first proper look at the Dexcom G8, and there is plenty here to get excited about.

At its 2026 Investor Day, Dexcom revealed a next-generation sensor that is expected to be 50% smaller than the Dexcom G7, while also promising a step-change in glucose performance, fewer outlier readings, and a new self-adapting sensor platform. The event took place on Thursday 14 May 2026.

Dexcom says G8 will be 50% smaller than G7, with additional sensing capabilities. Image: Dexcom Investor Day 2026.

For anyone who has ever tried to hide, protect, tape, rescue, bump, scrape or explain a CGM stuck to their body, “half the size” is not a small thing. Smaller devices usually mean more comfort, more clothing options, fewer doorframe betrayals, and a little less diabetes tech real estate on the body. That alone is worth a small confetti cannon.

What did Dexcom announce?

The headline features were:

A 50% smaller form factor than G7.

The G8 shown in Dexcom’s slides has a smaller, more rounded-square design. Dexcom presented it side by side with G7, making the size difference very clear.

Improved glucose performance.

Dexcom says G8 is designed to deliver a “step change improvement in glucose performance”, with significant accuracy improvements and fewer outlier readings. In practical terms, this matters because outlier readings are often the ones that cause the most stress: the sudden “that can’t be right” low, the confusing spike, or the number that sends you rummaging for a fingerprick meter at 2am.

A sensor that adapts during use.

Dexcom described G8 as both factory calibrated and self-adapting. Its slide says the sensor includes updated electronics and algorithm innovation that enable the sensor to adapt in real time. Independent diabetes technology coverage of the event reported that Dexcom expects this adaptive technology to improve consistency throughout wear.

Dexcom says G8 is designed to reduce MARD and reduce outlier readings. Image: Dexcom Investor Day 2026.

Can they make it smaller WITHOUT sacrificing connectivity?

This is the part where a lot of G7 users may raise an eyebrow.

Dexcom G7 was smaller and faster to warm up than G6, but some users have reported frustration with connectivity, brief sensor issues, and signal loss.

So the question is fair: if G7 already had connectivity complaints, can Dexcom really make G8 50% smaller and make it more reliable?

A smaller device can make antenna design and Bluetooth performance more challenging. That does not mean Dexcom cannot solve it, but it does mean the community will be watching closely. A tiny sensor is lovely. A tiny sensor that constantly drops out is a high-tech freckle.

That said, Dexcom has had years of real-world G7 feedback, and connectivity pain is not just a user problem. It creates support calls, replacement requests, reputational bruises and competitor opportunities. Dexcom would know better than anyone that G8 cannot simply be smaller. It needs to feel dependable.

If G8 delivers on both promises – smaller and steadier – it could be a genuinely exciting leap.

What about ketones?

One of the most interesting parts of Dexcom’s broader announcement was multi-analyte sensing.

Dexcom teased future sensors that could monitor more than glucose, including ketones and potassium. For people with type 1 diabetes, ketone monitoring is the obvious sparkle-flare. It could be particularly valuable during illness, pump failure, persistent highs, or any situation where diabetic ketoacidosis is a concern.

But Dexcom may not be first.

Abbott has already been developing a dual glucose-ketone sensor, described as a first-of-its-kind system that would continuously monitor glucose and ketones in one sensor. Abbott has said the sensor is the same size as its FreeStyle Libre 3 sensor, and may launch as early as this year.

Abbott also appears to be further along in building pump partnerships around this idea. Tandem, Beta Bionics and Ypsomed/CamDiab have all been reported as working toward future integration with Abbott’s glucose-ketone sensor platform.

So while Dexcom’s ketone promise is exciting, Abbott may beat them to market by a couple of years.

And potassium?

Potassium monitoring is the more unusual announcement.

For many people with type 1 diabetes, ketones will be the more immediately relatable feature. We already know why ketones matter. We already have sick-day plans built around them.

Potassium is different. It is clinically important, especially in areas like kidney disease, cardiac risk and DKA management, but it is not something most people with type 1 diabetes monitor day to day at home. If Dexcom can make continuous potassium monitoring work, it could be a significant innovation, but it may initially be of greater interest in type 2 diabetes, kidney disease, hospital-at-home care, or broader metabolic monitoring.

Still, it shows where the technology is heading. CGMs may not stay “CGMs” forever.

When will Dexcom G8 be released?

Dexcom says G8 is expected to launch in late 2027 or early 2028. That timing most likely refers to the first major launch markets, not Australia.

For Australia, history suggests we may be waiting longer. Dexcom G7 launched in its first international markets in late 2022, but did not become available in Australia until September 2024, with NDSS subsidy following in March 2025. That puts Australia roughly two years behind the earliest G7 markets.

Dexcom expects G8 to launch in late 2027 or early 2028. Image: Dexcom Investor Day 2026.

If G8 follows a similar pattern, an Australian launch could land sometime in 2029, with NDSS access potentially coming later. A faster rollout could bring it closer to late 2028, but until Dexcom announces local timing, 2029 is probably the more realistic expectation.

The bottom line

Dexcom G8 is still some way off, especially for Australia. But this announcement gives us a clear glimpse of where Dexcom is heading: smaller sensors, fewer outlier readings, and eventually, more than glucose.

For the type 1 community, the size reduction is the immediate headline. A sensor that is half the size of G7 is worth celebrating. The adaptive accuracy claims are promising, but untested. The future of ketone monitoring is genuinely exciting.

The caution is simple: G8 will need to prove itself in real life, not just on investor slides. But if Dexcom can deliver what it's promising, G8 could be a very big deal in a very small package.